EL7.AI
StocksMediumUpdated×3•Originally published 2 October 2026•Updated 2 October 2026•
1 min read

Integra LifeSciences Stock Tumbles on 2026 Guidance Cut

Key Facts

1Integra LifeSciences announced the launch of a $600 million seven-year Senior Secured Term Loan B as part of a broader refinancing transaction.

Integra LifeSciences stock price tumbled following the company's decision to cut its financial outlook for the full year 2026. The company stated in an official release that the downward revision was issued alongside its preliminary unaudited financial results for the third quarter.

The decline follows a close for IART shares at $16.09 on October 1, 2026, prior to the negative reaction to the guidance cut. These developments coincide with the company's launch of a $600 million seven-year Senior Secured Term Loan B, intended to refinance existing debt and support the company's financial structure under the revised outlook.

Latest Updates · 1

  1. Notable·

    Update: The company narrowed its 2026 annual revenue guidance to a range of $1.634 billion to $1.654 billion. Integra LifeSciences attributed this revision to operational disruptions at its Cincinnati facility following flooding that occurred in July.